# Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC

> **NCT03253133** · PHASE1 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 19 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** LV5FU or Folfiri
- **DRUG:** Oxycodone

## Key facts

- **NCT ID:** NCT03253133
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-10
- **Primary completion:** 2020-10-28
- **Final completion:** 2023-04-24
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03253133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03253133, "Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03253133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*